September marks National ITP Awareness Month, and, Wayrilz (rilzabrutinib) was just approved by the US Food and Drug Administration (FDA) as a novel treatment for adults with persistent or chronic ITP who have had an insufficient response to earlier treatments. Wayrilz works by modulating various parts of the immune system to help address the underlying causes of ITP.

Amit Mehta, MD, hematologist and oncologist, describes the symptoms you should look for, how ITP can affect many aspects of your life, and how the new FDA approved drug Wayrilz is a first in understanding the source of ITP and addressing its underlying triggers.

Learn about Wayrilz: https://bit.ly/wayrilz 

Learn more about ITP: https://bit.ly/bruising-and-ITP

If you're enjoying the Show, it would mean the world to us if you took a second to leave a five star review on YouTube, Apple Podcasts, or Spotify, or wherever you're listening to us. It helps more people find the show and lets us know we're on the right track. We thank you in advance

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.